Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Shares Outstanding (2020 - 2025)

Insight Molecular Diagnostics' Shares Outstanding history spans 6 years, with the latest figure at $28.6 million for Q3 2025.

  • For Q3 2025, Shares Outstanding rose 114.03% year-over-year to $28.6 million; the TTM value through Sep 2025 reached $28.6 million, up 114.03%, while the annual FY2024 figure was $17.5 million, 111.27% up from the prior year.
  • Shares Outstanding for Q3 2025 was $28.6 million at Insight Molecular Diagnostics, roughly flat from $28.6 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $118.6 million in Q3 2022 and bottomed at $5000.0 in Q2 2023.
  • The 5-year median for Shares Outstanding is $13.4 million (2024), against an average of $29.0 million.
  • The largest annual shift saw Shares Outstanding plummeted 99.92% in 2024 before it surged 571880.0% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $4.6 million in 2021, then tumbled by 99.87% to $6000.0 in 2022, then skyrocketed by 137583.33% to $8.3 million in 2023, then surged by 111.27% to $17.5 million in 2024, then skyrocketed by 64.01% to $28.6 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Shares Outstanding are $28.6 million (Q3 2025), $28.6 million (Q2 2025), and $28.6 million (Q1 2025).